Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer

Purpose This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, a...

詳細記述

書誌詳細

主要な著者:	Ashraf Mahmoud El-Enbaby, Nadia Ahmed Abd El Moneim, Gehan Abd El atti Khedr, Yasmine Mohamed Nagy Elwany
フォーマット:	Artigo
言語:	Inglês
出版事項:	Korean Society of Surgical Oncology 2018-12-01
シリーズ:	Korean Journal of Clinical Oncology
主題:	trastuzumab her2 adjuvant chemotherapy radiotherapy echocardiography
オンライン･アクセス:	http://www.kjco.org/upload/kjco-14-2-108.pdf
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!